Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1195)	6/23/1998 9:17:00 AM
From: scaram(o)uche	Read Replies (2) \| Respond to of 2742

Message 4973454 Galton, you would now be one of two reagents companies in the world with rights to sell IL-2. And, you would be in control of reagent flowing to the second. Once again, I was V.P Product Development at your competitor (I use that term lightly, as it would take a pimple on my butt to compete effectively with you), PharMingen. As you should know, but probably don't, PharMingen was purchased by Becton Dickinson for $70 million a few years after being bootstrapped from family loans. You are in a class by yourself.